Pancreatic Cancer: Yesterday, Today and Tomorrow

References

• Morgagni G . De Sedibus, et Causis Morborum per Anatomen Indagatis Libri Quinque. Venetiis, Typog Remondiniana (1761).
   Google Scholar
• Da Costa J . On the Morbid Anatomy and Symptoms of Cancer of the Pancreas. JB Lippincott & Company, Philadelphia, PA, USA (1858).
   Google Scholar
• Codivilla A . Rendiconto statistico della sezione chirurgica dell’ospedale di Imola. Imola, Italy (1898).
   Google Scholar
• Halsted W . Contributions to the surgery of the bile passages, especially of the common bile-duct. Boston Med. Surg. J.141, 645–654 (1899).
   Google Scholar
• Kausch W . Das carcinom der papilla duodeni und seine radikale entfernung. Beitr. Klin. Chir.78, 439–486 (1912).
   Google Scholar
• Hirschel G . Die resektion des duodenums mit der papille wegen karzinoms. Munch. Med. Wochenschr.61, 1728–1729 (1914).
   Google Scholar
• Whipple AO , ParsonsWB, MullinsCR. Treatment of Carcinoma of the ampulla of vater. Ann. Surg.102(4), 763–779 (1935).
   PubMedGoogle Scholar
• Whipple AO . Observations on radical surgery for lesions of the pancreas. Surg. Gynecol. Obstet.82, 623–631 (1946).
   PubMedGoogle Scholar
• Whipple AO . A reminiscence: pancreaticduodenectomy. Rev. Surg.20, 221–225 (1963).
   PubMedGoogle Scholar
• Brunschwig A . Resection of the head of pancreas and duodenum for carcinoma – pancreatoduodenectomy. Surg. Gynecol. Obstet.65, 681–684 (1937).
   Google Scholar
• Ansari D , WilliamssonC, TingstedtB, AnderssonB, LindellG, AnderssonR. Pancreaticoduodenectomy – the transition from a low- to a high-volume center. Scand. J. Gastroenterol.49(4), 481–484 (2014).
   PubMed Web of Science ®Google Scholar
• Balzano G , ZerbiA, CaprettiG, RocchettiS, CapitanioV, Di CarloV. Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br. J. Surg.95(3), 357–362 (2008).
   PubMed Web of Science ®Google Scholar
• Yoshioka R , YasunagaH, HasegawaKet al. Impact of hospital volume on hospital mortality, length of stay and total costs after pancreaticoduodenectomy. Br. J. Surg.101(5), 523–529 (2014).
   PubMed Web of Science ®Google Scholar
• Rahib L , SmithBD, AizenbergR, RosenzweigAB, FleshmanJM, MatrisianLM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res.74(11), 2913–2921 (2014).
   PubMed Web of Science ®Google Scholar
• Malvezzi M , BertuccioP, RossoTet al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann. Oncol. 26(4), 779–786 (2015).
   PubMed Web of Science ®Google Scholar
• Engholm G , FerlayJ, ChristensenNet al. NORDCAN – a Nordic tool for cancer information, planning, quality control and research. Acta Oncol.49(5), 725–736 (2010).
   PubMed Web of Science ®Google Scholar
• Becker AE , HernandezYG, FruchtH, LucasAL. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J. Gastroenterol.20(32), 11182–11198 (2014).
   PubMed Web of Science ®Google Scholar
• Nitsche C , SimonP, WeissFUet al. Environmental risk factors for chronic pancreatitis and pancreatic cancer. Dig. Dis.29(2), 235–242 (2011).
   PubMed Web of Science ®Google Scholar
• Bracci PM . Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol. Carcinog.51(1), 53–63 (2012).
   PubMed Web of Science ®Google Scholar
• Raimondi S , LowenfelsAB, Morselli-LabateAM, MaisonneuveP, PezzilliR. Pancreatic cancer in chronic pancreatitis: aetiology, incidence, and early detection. Best Pract. Res. Clin. Gastroenterol.24(3), 349–358 (2010).
   PubMed Web of Science ®Google Scholar
• Lucenteforte E , La VecchiaC, SilvermanDet al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case–Control Consortium (PanC4). Ann. Oncol.23(2), 374–382 (2012).
   PubMed Web of Science ®Google Scholar
• Tramacere I , ScottiL, JenabMet al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int. J. Cancer126(6), 1474–1486 (2010).
   PubMed Web of Science ®Google Scholar
• Everhart J , WrightD. Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA273(20), 1605–1609 (1995).
   PubMed Web of Science ®Google Scholar
• Bartosch-Harlid A , AnderssonR. Diabetes mellitus in pancreatic cancer and the need for diagnosis of asymptomatic disease. Pancreatology10(4), 423–428 (2010).
   PubMed Web of Science ®Google Scholar
• Hruban RH , MaitraA, KernSE, GogginsM. Precursors to pancreatic cancer. Gastroenterol. Clin. North Am.36(4), 831–849, vi (2007).
   PubMed Web of Science ®Google Scholar
• Klein AP . Identifying people at a high risk of developing pancreatic cancer. Nat. Rev. Cancer13(1), 66–74 (2013).
   PubMed Web of Science ®Google Scholar
• Yachida S , JonesS, BozicIet al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature467(7319), 1114–1117 (2010).
   PubMed Web of Science ®Google Scholar
• AJCC Cancer Staging Manual (7th Edition) . Springer, NY, USA (2010).
   Google Scholar
• Wittekind C , ComptonCC, GreeneFL, SobinLH. TNM residual tumor classification revisited. Cancer94(9), 2511–2516 (2002).
   PubMed Web of Science ®Google Scholar
• Chari ST , KellyK, HollingsworthMAet al. Early detection of sporadic pancreatic cancer: summative review. Pancreas44(5), 693–712 (2015).
   PubMed Web of Science ®Google Scholar
• Siegel RL , MillerKD, JemalA. Cancer statistics, 2015. CA Cancer J. Clin.65(1), 5–29 (2015).
   PubMed Web of Science ®Google Scholar
• Canto MI , HarinckF, HrubanRHet al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut62(3), 339–347 (2013).
   PubMed Web of Science ®Google Scholar
• Bruenderman EH , MartinRC2nd. High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening. J. Surg. Res.194(1), 212–219 (2015).
   PubMed Web of Science ®Google Scholar
• Goonetilleke KS , SiriwardenaAK. Systematic review of carbohydrate antigen (CA 19-19) as a biochemical marker in the diagnosis of pancreatic cancer. Eur. J. Surg. Oncol.33(3), 266–270 (2007).
   PubMed Web of Science ®Google Scholar
• Duffy MJ , SturgeonC, LamerzRet al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann. Oncol.21(3), 441–447 (2010).
   PubMed Web of Science ®Google Scholar
• Klauss M , StillerW, PahnGet al. Dual-energy perfusion-CT of pancreatic adenocarcinoma. Eur. J. Radiol.82(2), 208–214 (2013).
   PubMed Web of Science ®Google Scholar
• Ichikawa T , SouH, ArakiTet al. Duct-penetrating sign at MRCP: usefulness for differentiating inflammatory pancreatic mass from pancreatic carcinomas. Radiology221(1), 107–116 (2001).
   PubMed Web of Science ®Google Scholar
• Barral M , TaouliB, GuiuBet al. Diffusion-weighted MR imaging of the pancreas: current status and recommendations. Radiology274(1), 45–63 (2015).
   PubMed Web of Science ®Google Scholar
• Yasuda I , IwashitaT, DoiS, NakashimaM, MoriwakiH. Role of EUS in the early detection of small pancreatic cancer. Dig. Endosc.23(Suppl. 1), 22–25 (2011).
   PubMedGoogle Scholar
• Pappas SG , ChristiansKK, TolatPPet al. Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? HPB 16(1), 70–74 (2014).
   PubMed Web of Science ®Google Scholar
• Kramer-Marek G , GoreJ, KorcM. Molecular imaging in pancreatic cancer: a roadmap for therapeutic decisions. Cancer Lett.341(2), 132–138 (2013).
   PubMed Web of Science ®Google Scholar
• England CG , HernandezR, EddineSB, CaiW. Molecular imaging of pancreatic cancer with antibodies. Mol. Pharm.13(1), 8–24 (2016).
   PubMedGoogle Scholar
• Al-Hawary MM , FrancisIR, ChariSTet al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology270(1), 248–260 (2014).
   PubMed Web of Science ®Google Scholar
• Ansari D , AronssonL, FredrikssonJ, AnderssonB, AnderssonR. Safety of pancreatic resection in the elderly: a retrospective analysis of 556 patients. Ann. Gastroenterol.29(2), 221–225 (2016).
   PubMedGoogle Scholar
• Junejo MA , MasonJM, SheenAJet al. Cardiopulmonary exercise testing for preoperative risk assessment before pancreaticoduodenectomy for cancer. Ann. Surg. Oncol.21(6), 1929–1936 (2014).
   PubMed Web of Science ®Google Scholar
• Argiles JM . Cancer-associated malnutrition. Eur. J. Oncol. Nurs.9(Suppl. 2), S39–S50 (2005).
   PubMedGoogle Scholar
• La Torre M , ZiparoV, NigriG, CavalliniM, BalducciG, RamacciatoG. Malnutrition and pancreatic surgery: prevalence and outcomes. J. Surg. Oncol.107(7), 702–708 (2013).
   PubMed Web of Science ®Google Scholar
• Joglekar S , AsgharA, MottSLet al. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J. Surg. Oncol.111(6), 771–775 (2015).
   PubMed Web of Science ®Google Scholar
• Van Der Gaag NA , RauwsEA, Van EijckCHet al. Preoperative biliary drainage for cancer of the head of the pancreas. N. Engl. J. Med.362(2), 129–137 (2010).
   PubMed Web of Science ®Google Scholar
• Tol JA , Van HooftJE, TimmerRet al. Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer. Gut doi: 10.1136/gutjnl-2014-308762 (2015) ( Epub ahead of print).
   Google Scholar
• Sauvanet A , BoherJM, PayeFet al. Severe jaundice increases early severe morbidity and decreases long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. J. Am. Coll. Surg.221(2), 380–389 (2015).
   PubMed Web of Science ®Google Scholar
• Xiong JJ , TanCL, SzatmaryPet al. Meta-analysis of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Br. J. Surg.101(10), 1196–1208 (2014).
   PubMed Web of Science ®Google Scholar
• Menahem B , GuittetL, MulliriA, AlvesA, LubranoJ. Pancreaticogastrostomy is superior to pancreaticojejunostomy for prevention of pancreatic fistula after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. Ann. Surg.261(5), 882–887 (2015).
   PubMed Web of Science ®Google Scholar
• Roberts KJ , HodsonJ, MehrzadHet al. A preoperative predictive score of pancreatic fistula following pancreatoduodenectomy. HPB16(7), 620–628 (2014).
   PubMed Web of Science ®Google Scholar
• Ansorge C , StrommerL, Andren-SandbergA, LundellL, HerringtonMK, SegersvardR. Structured intraoperative assessment of pancreatic gland characteristics in predicting complications after pancreaticoduodenectomy. Br. J. Surg.99(8), 1076–1082 (2012).
   PubMed Web of Science ®Google Scholar
• Chan C , FranssenB, DominguezI, Ramirez-Del ValA, UscangaLF, CampuzanoM. Impact on quality of life after pancreatoduodenectomy: a prospective study comparing preoperative and postoperative scores. J. Gastrointest. Surg.16(7), 1341–1346 (2012).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version 2 (2015). www.nccn.org/professionals/physician_gls/f_guidelines.asp.
   Google Scholar
• Mahipal A , FrakesJ, HoffeS, KimR. Management of borderline resectable pancreatic cancer. World. J. Gastrointest. Oncol.7(10), 241–249 (2015).
   PubMed Web of Science ®Google Scholar
• Bockhorn M , UzunogluFG, AdhamMet al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery155(6), 977–988 (2014).
   PubMed Web of Science ®Google Scholar
• Moore GE , SakoY, ThomasLB. Radical pancreatoduodenectomy with resection and reanastomosis of the superior mesenteric vein. Surgery30(3), 550–553 (1951).
   PubMed Web of Science ®Google Scholar
• Asada S , ItayaH, NakamuraK, IsohashiT, MasuokaS. Radical pancreatoduodenectomy and portal vein resection. report of two successful cases with transplantation of portal vein. Arch. Surg.87, 609–613 (1963).
   PubMedGoogle Scholar
• Fortner JG . Regional resection of cancer of the pancreas: a new surgical approach. Surgery73(2), 307–320 (1973).
   PubMed Web of Science ®Google Scholar
• Zhou Y , ZhangZ, LiuY, LiB, XuD. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J. Surg.36(4), 884–891 (2012).
   PubMed Web of Science ®Google Scholar
• Kim SM , MinSK, ParkDet al. Reconstruction of portal vein and superior mesenteric vein after extensive resection for pancreatic cancer. J. Korean Surg. Soc.84(6), 346–352 (2013).
   PubMedGoogle Scholar
• Glebova NO , HicksCW, PiazzaKMet al. Technical risk factors for portal vein reconstruction thrombosis in pancreatic resection. J. Vasc. Surg.62(2), 424–433 (2015).
   PubMed Web of Science ®Google Scholar
• Fujii T , NakaoA, YamadaSet al. Vein resections >3 cm during pancreatectomy are associated with poor 1-year patency rates. Surgery157(4), 708–715 (2015).
   PubMed Web of Science ®Google Scholar
• Ferreira N , OussoultzoglouE, FuchshuberPet al. Splenic vein-inferior mesenteric vein anastomosis to lessen left-sided portal hypertension after pancreaticoduodenectomy with concomitant vascular resection. Arch. Surg.146(12), 1375–1381 (2011).
   PubMedGoogle Scholar
• Mollberg N , RahbariNN, KochMet al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann. Surg.254(6), 882–893 (2011).
   PubMed Web of Science ®Google Scholar
• Tol JA , GoumaDJ, BassiCet al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery156(3), 591–600 (2014).
   PubMed Web of Science ®Google Scholar
• Dasari BV , PasqualiS, VohraRSet al. Extended versus standard lymphadenectomy for pancreatic head cancer: meta-analysis of randomized controlled trials. J. Gastrointest. Surg.19(9), 1725–1732 (2015).
   PubMed Web of Science ®Google Scholar
• Williamsson C , KarlssonN, SturessonC, LindellG, AnderssonR, TingstedtB. Impact of a fast-track surgery programme for pancreaticoduodenectomy. Br. J. Surg.102(9), 1133–1141 (2015).
   PubMed Web of Science ®Google Scholar
• Ansari D , GianottiL, SchroderJ, AnderssonR. Fast-track surgery: procedure-specific aspects and future direction. Langenbecks Arch. Surg.398(1), 29–37 (2013).
   PubMed Web of Science ®Google Scholar
• Andersson R , VagianosCE, WilliamsonRC. Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB6(1), 5–12 (2004).
   PubMedGoogle Scholar
• Poruk KE , FirpoMA, AdlerDG, MulvihillSJ. Screening for pancreatic cancer: why, how, and who?Ann. Surg.257(1), 17–26 (2013).
   PubMed Web of Science ®Google Scholar
• Strobel O , HinzU, GluthAet al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann. Surg.261(5), 961–969 (2015).
   PubMed Web of Science ®Google Scholar
• Basturk O , SakaB, BalciSet al. Substaging of lymph node status in resected pancreatic ductal adenocarcinoma has strong prognostic correlations: proposal for a revised N classification for TNM staging. Ann. Surg. Oncol.22(Suppl. 3), S1187–S1195 (2015).
   PubMedGoogle Scholar
• Crippa S , PartelliS, ZamboniGet al. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile? Surgery 152(3 Suppl. 1), S112–S119 (2012).
   PubMed Web of Science ®Google Scholar
• Hruban RH , FukushimaN. Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. Mod. Pathol.20(Suppl. 1), S61–S70 (2007).
   PubMedGoogle Scholar
• Chen JW , BhandariM, AstillDSet al. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB12(2), 101–108 (2010).
   PubMed Web of Science ®Google Scholar
• Esposito I , KleeffJ, BergmannFet al. Most pancreatic cancer resections are R1 resections. Ann. Surg. Oncol.15(6), 1651–1660 (2008).
   PubMed Web of Science ®Google Scholar
• Verbeke CS , LeitchD, MenonKV, McmahonMJ, GuillouPJ, AnthoneyA. Redefining the R1 resection in pancreatic cancer. Br. J. Surg.93(10), 1232–1237 (2006).
   PubMed Web of Science ®Google Scholar
• Chandrasegaram MD , GoldsteinD, SimesJet al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br. J. Surg.102(12), 1459–1472 (2015).
   PubMed Web of Science ®Google Scholar
• Kalser MH , EllenbergSS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg.120(8), 899–903 (1985).
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP , StockenDD, FriessHet al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med.350(12), 1200–1210 (2004).
   PubMed Web of Science ®Google Scholar
• Oettle H , NeuhausP, HochhausAet al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA310(14), 1473–1481 (2013).
   PubMed Web of Science ®Google Scholar
• Oettle H , PostS, NeuhausPet al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA297(3), 267–277 (2007).
   PubMed Web of Science ®Google Scholar
• Regine WF , WinterKA, AbramsRAet al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA299(9), 1019–1026 (2008).
   PubMed Web of Science ®Google Scholar
• Regine WF , WinterKA, AbramsRet al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 Phase III trial. Ann. Surg. Oncol.18(5), 1319–1326 (2011).
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP , StockenDD, BassiCet al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA304(10), 1073–1081 (2010).
   PubMed Web of Science ®Google Scholar
• Fukutomi A , UesakaK, BokuNet al. JASPAC 01: randomized Phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J. Clin. Oncol.31(Suppl. 15), 4008 (2013).
   Web of Science ®Google Scholar
• Huguet F , AndreT, HammelPet al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III studies. J. Clin. Oncol.25(3), 326–331 (2007).
   PubMed Web of Science ®Google Scholar
• Krishnan S , RanaV, JanjanNAet al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer110(1), 47–55 (2007).
   PubMed Web of Science ®Google Scholar
• Hammel P , HuguetF, Van LaethemJet al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international Phase III LAP 07 study. J. Clin. Oncol.31(Suppl. 18), Abstract LBA4003 (2013).
   Web of Science ®Google Scholar
• Burris HA 3rd , MooreMJ, AndersenJet al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol.15(6), 2403–2413 (1997).
   PubMed Web of Science ®Google Scholar
• Moore MJ , GoldsteinD, HammJet al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25(15), 1960–1966 (2007).
   PubMed Web of Science ®Google Scholar
• Conroy T , DesseigneF, YchouMet al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med.364(19), 1817–1825 (2011).
   PubMed Web of Science ®Google Scholar
• Von Hoff DD , ErvinT, ArenaPFet al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med.369(18), 1691–1703 (2013).
   PubMed Web of Science ®Google Scholar
• Pelzer U , SchwanerI, StielerJet al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a Phase III-study from the German CONKO-study group. Eur. J. Cancer47(11), 1676–1681 (2011).
   PubMed Web of Science ®Google Scholar
• Oettle H , RiessH, StielerJMet al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J. Clin. Oncol.32(23), 2423–2429 (2014).
   PubMed Web of Science ®Google Scholar
• Gill S , KoY, CrippsMet al. PANCREOX: a randomized Phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). J. Clin. Oncol.32(15), 4022 (2014).
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A , LiCP, BodokyGet al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, Phase 3 trial. Lancet doi: 10.1016/S0140-6736(15)00986-00981 (2015) ( Epub ahead of print).
   Google Scholar
• Ueno H , IokaT, IkedaMet al. Randomized Phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J. Clin. Oncol.31(13), 1640–1648 (2013).
   PubMed Web of Science ®Google Scholar
• Haywood A , GoodP, KhanSet al. Corticosteroids for the management of cancer-related pain in adults. Cochrane Database Syst. Rev.4, CD010756 (2015).
   Google Scholar
• Johnson CD , BerryDP, HarrisSet al. An open randomized comparison of clinical effectiveness of protocol-driven opioid analgesia, celiac plexus block or thoracoscopic splanchnicectomy for pain management in patients with pancreatic and other abdominal malignancies. Pancreatology9(6), 755–763 (2009).
   PubMed Web of Science ®Google Scholar
• Mercadante S , KlepstadP, KuritaGP, SjogrenP, GiarratanoA. European Palliative Care Research C. Sympathetic blocks for visceral cancer pain management: a systematic review and EAPC recommendations. Crit. Rev. Oncol. Hematol. doi: 10.1016/j.critrevonc.07.014 (2015) ( Epub ahead of print).
   Google Scholar
• Bruno MJ , HaverkortEB, TijssenGP, TytgatGN, Van LeeuwenDJ. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut42(1), 92–96 (1998).
   PubMed Web of Science ®Google Scholar
• Davidson W , AshS, CapraS, BauerJ, Cancer Cachexia StudyG. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin. Nutr.23(2), 239–247 (2004).
   PubMed Web of Science ®Google Scholar
• Yennurajalingam S , Frisbee-HumeS, PalmerJLet al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J. Clin. Oncol.31(25), 3076–3082 (2013).
   PubMed Web of Science ®Google Scholar
• Moss AC , MorrisE, Mac MathunaP. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst. Rev.2, CD004200 (2006).
   Google Scholar
• Williamsson C , WennerblomJ, TingstedtB, JonssonC. A wait-and-see strategy with subsequent self-expanding metal stent on demand is superior to prophylactic bypass surgery for unresectable periampullary cancer. HPB doi: 10.1111/hpb.12513 (2015) ( Epub ahead of print).
   Google Scholar
• Ansari D , AnderssonR, BaudenMPet al. Protein deep sequencing applied to biobank samples from patients with pancreatic cancer. J. Cancer Res. Clin. Oncol.141(2), 369–380 (2015).
   PubMed Web of Science ®Google Scholar
• Jones S , ZhangX, ParsonsDWet al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science321(5897), 1801–1806 (2008).
   PubMed Web of Science ®Google Scholar
• Waddell N , PajicM, PatchAMet al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature518(7540), 495–501 (2015).
   PubMed Web of Science ®Google Scholar
• Biankin AV , WaddellN, KassahnKSet al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature491(7424), 399–405 (2012).
   PubMed Web of Science ®Google Scholar
• Hoskins JW , JiaJ, FlandezMet al. Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A. Carcinogenesis35(12), 2670–2678 (2014).
   PubMed Web of Science ®Google Scholar
• Daemen A , PetersonD, SahuNet al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc. Natl Acad. Sci. USA112(32), E4410–4417 (2015).
   PubMed Web of Science ®Google Scholar
• Eltawil KM , RenfrewPD, MolinariM. Meta-analysis of Phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. HPB14(4), 260–268 (2012).
   PubMed Web of Science ®Google Scholar
• Zorde Khvalevsky E , GabaiR, RachmutIHet al. Mutant KRAS is a druggable target for pancreatic cancer. Proc. Natl Acad. Sci. USA110(51), 20723–20728 (2013).
   PubMed Web of Science ®Google Scholar
• Xie D , XieK. Pancreatic cancer stromal biology and therapy. Genes Dis.2(2), 133–143 (2015).
   PubMed Web of Science ®Google Scholar
• Hingorani S , HarrisW, HendifarAet al. High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized Phase II study. J. Clin. Oncol.33(Suppl.), Abstract 4006 (2015).
   Google Scholar
• Hingorani S , HarrisW, BeckJet al. Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer. J. Clin. Oncol.33(Suppl. 3), Abstract 359 (2015).
   Web of Science ®Google Scholar
• Amedei A , NiccolaiE, PriscoD. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum. Vaccin. Immunother.10(11), 3354–3368 (2014).
   PubMed Web of Science ®Google Scholar
• Houot R , SchultzLM, MarabelleA, KohrtH. T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol. Res.3(10), 1115–1122 (2015).
   PubMed Web of Science ®Google Scholar
• Lutz ER , KinkeadH, JaffeeEM, ZhengL. Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. Oncoimmunology3(11), e962401 (2014).
   PubMed Web of Science ®Google Scholar
• Kure S , MatsudaY, HagioM, UedaJ, NaitoZ, IshiwataT. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas. Int. J. Oncol.41(4), 1314–1324 (2012).
   PubMed Web of Science ®Google Scholar
• Mohammed A , JanakiramNB, PantS, RaoCV. Molecular targeted intervention for pancreatic cancer. Cancers (Basel)7(3), 1499–1542 (2015).
   PubMed Web of Science ®Google Scholar
• Raj D , AicherA, HeeschenC. Concise review: stem cells in pancreatic cancer: from concept to translation. Stem Cells33(10), 2893–2902 (2015).
   PubMed Web of Science ®Google Scholar
• Warburg O , WindF, NegeleinE. The metabolism of tumors in the body. J. Gen. Physiol.8(6), 519–530 (1927).
   PubMedGoogle Scholar
• Warburg O . On the metabolism of carcinoma cells. Biochem. Z.152, 309–344 (1924).
   Google Scholar
• Blum R , KloogY. Metabolism addiction in pancreatic cancer. Cell Death Dis.5, e1065 (2014).
   PubMed Web of Science ®Google Scholar
• Son J , LyssiotisCA, YingHet al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature496(7443), 101–105 (2013).
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG . Exploiting tumor metabolism: challenges for clinical translation. J. Clin. Invest.123(9), 3648–3651 (2013).
   PubMed Web of Science ®Google Scholar
• Yu M , ZhouQ, ZhouYet al. Metabolic phenotypes in pancreatic cancer. PLoS ONE10(2), e0115153 (2015).
   PubMed Web of Science ®Google Scholar
• Lee GY , QianWP, WangLet al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano7(3), 2078–2089 (2013).
   PubMed Web of Science ®Google Scholar
• Hanahan D , WeinbergRA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).
   PubMed Web of Science ®Google Scholar